Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

Alberto Farolfi, Emanuela Scarpi, Andrea Rocca, Anita Mangia, Nicoletta Biglia, Lorenzo Gianni, Amelia Tienghi, Maria Rosaria Valerio, Giampietro Gasparini, Laura Amaducci, Marina Faedi, Editta Baldini, Alessandra Rubagotti, Roberta Maltoni, Angelo Paradiso, Dino Amadori

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) were calculated by the Kaplan-Meier method. Multivariate Cox analysis was performed in relation with nodal involvement, oestrogen receptor and human epidermal growth factor receptor 2 (HER2) status, Ki67 value, type of adjuvant chemotherapy, menopausal status and tumour size. Results At a median follow-up of 105 months (range 2-188), a prolonged TTC resulted in a significant increase in the risk of relapse: hazard ratio (HR) 1.15 (95% CI 1.02-1.30, p = 0.019). Using a backward elimination procedure, TTC, tumour size and nodal involvement remained significantly associated with DFS. A time-dependent receiver-operating characteristic (ROC) curve analysis was subsequently utilised to evaluate the best cut-off for TTC, identifying 7 weeks as the best threshold for longer OS (p = 0.043): 8-year OS 88% (95% CI 85-90) for patients with a TTC

Original languageEnglish
Article number9535
Pages (from-to)1874-1881
Number of pages8
JournalEuropean Journal of Cancer
Volume51
Issue number14
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Adjuvant Chemotherapy
Methotrexate
Fluorouracil
Confidence Intervals
Cyclophosphamide
Breast Neoplasms
Epirubicin
Survival
Drug Therapy
Neoplasms
Phase III Clinical Trials
Anthracyclines
ROC Curve
Estrogen Receptors
Thymidine
Multivariate Analysis
Recurrence

Keywords

  • Adjuvant chemotherapy
  • Early breast cancer
  • Rapidly proliferating tumour
  • Time to initiation of adjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. / Farolfi, Alberto; Scarpi, Emanuela; Rocca, Andrea; Mangia, Anita; Biglia, Nicoletta; Gianni, Lorenzo; Tienghi, Amelia; Valerio, Maria Rosaria; Gasparini, Giampietro; Amaducci, Laura; Faedi, Marina; Baldini, Editta; Rubagotti, Alessandra; Maltoni, Roberta; Paradiso, Angelo; Amadori, Dino.

In: European Journal of Cancer, Vol. 51, No. 14, 9535, 01.07.2015, p. 1874-1881.

Research output: Contribution to journalArticle

Farolfi, A, Scarpi, E, Rocca, A, Mangia, A, Biglia, N, Gianni, L, Tienghi, A, Valerio, MR, Gasparini, G, Amaducci, L, Faedi, M, Baldini, E, Rubagotti, A, Maltoni, R, Paradiso, A & Amadori, D 2015, 'Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer', European Journal of Cancer, vol. 51, no. 14, 9535, pp. 1874-1881. https://doi.org/10.1016/j.ejca.2015.07.003
Farolfi, Alberto ; Scarpi, Emanuela ; Rocca, Andrea ; Mangia, Anita ; Biglia, Nicoletta ; Gianni, Lorenzo ; Tienghi, Amelia ; Valerio, Maria Rosaria ; Gasparini, Giampietro ; Amaducci, Laura ; Faedi, Marina ; Baldini, Editta ; Rubagotti, Alessandra ; Maltoni, Roberta ; Paradiso, Angelo ; Amadori, Dino. / Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. In: European Journal of Cancer. 2015 ; Vol. 51, No. 14. pp. 1874-1881.
@article{356bea0fd48044a4a5e12d8d8a739f31,
title = "Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer",
abstract = "Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3{\%} or G3 or Ki67 >20{\%}), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95{\%} confidence intervals (95{\%} confidence interval (CI)) were calculated by the Kaplan-Meier method. Multivariate Cox analysis was performed in relation with nodal involvement, oestrogen receptor and human epidermal growth factor receptor 2 (HER2) status, Ki67 value, type of adjuvant chemotherapy, menopausal status and tumour size. Results At a median follow-up of 105 months (range 2-188), a prolonged TTC resulted in a significant increase in the risk of relapse: hazard ratio (HR) 1.15 (95{\%} CI 1.02-1.30, p = 0.019). Using a backward elimination procedure, TTC, tumour size and nodal involvement remained significantly associated with DFS. A time-dependent receiver-operating characteristic (ROC) curve analysis was subsequently utilised to evaluate the best cut-off for TTC, identifying 7 weeks as the best threshold for longer OS (p = 0.043): 8-year OS 88{\%} (95{\%} CI 85-90) for patients with a TTC",
keywords = "Adjuvant chemotherapy, Early breast cancer, Rapidly proliferating tumour, Time to initiation of adjuvant chemotherapy",
author = "Alberto Farolfi and Emanuela Scarpi and Andrea Rocca and Anita Mangia and Nicoletta Biglia and Lorenzo Gianni and Amelia Tienghi and Valerio, {Maria Rosaria} and Giampietro Gasparini and Laura Amaducci and Marina Faedi and Editta Baldini and Alessandra Rubagotti and Roberta Maltoni and Angelo Paradiso and Dino Amadori",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.ejca.2015.07.003",
language = "English",
volume = "51",
pages = "1874--1881",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "14",

}

TY - JOUR

T1 - Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

AU - Farolfi, Alberto

AU - Scarpi, Emanuela

AU - Rocca, Andrea

AU - Mangia, Anita

AU - Biglia, Nicoletta

AU - Gianni, Lorenzo

AU - Tienghi, Amelia

AU - Valerio, Maria Rosaria

AU - Gasparini, Giampietro

AU - Amaducci, Laura

AU - Faedi, Marina

AU - Baldini, Editta

AU - Rubagotti, Alessandra

AU - Maltoni, Roberta

AU - Paradiso, Angelo

AU - Amadori, Dino

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) were calculated by the Kaplan-Meier method. Multivariate Cox analysis was performed in relation with nodal involvement, oestrogen receptor and human epidermal growth factor receptor 2 (HER2) status, Ki67 value, type of adjuvant chemotherapy, menopausal status and tumour size. Results At a median follow-up of 105 months (range 2-188), a prolonged TTC resulted in a significant increase in the risk of relapse: hazard ratio (HR) 1.15 (95% CI 1.02-1.30, p = 0.019). Using a backward elimination procedure, TTC, tumour size and nodal involvement remained significantly associated with DFS. A time-dependent receiver-operating characteristic (ROC) curve analysis was subsequently utilised to evaluate the best cut-off for TTC, identifying 7 weeks as the best threshold for longer OS (p = 0.043): 8-year OS 88% (95% CI 85-90) for patients with a TTC

AB - Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) were calculated by the Kaplan-Meier method. Multivariate Cox analysis was performed in relation with nodal involvement, oestrogen receptor and human epidermal growth factor receptor 2 (HER2) status, Ki67 value, type of adjuvant chemotherapy, menopausal status and tumour size. Results At a median follow-up of 105 months (range 2-188), a prolonged TTC resulted in a significant increase in the risk of relapse: hazard ratio (HR) 1.15 (95% CI 1.02-1.30, p = 0.019). Using a backward elimination procedure, TTC, tumour size and nodal involvement remained significantly associated with DFS. A time-dependent receiver-operating characteristic (ROC) curve analysis was subsequently utilised to evaluate the best cut-off for TTC, identifying 7 weeks as the best threshold for longer OS (p = 0.043): 8-year OS 88% (95% CI 85-90) for patients with a TTC

KW - Adjuvant chemotherapy

KW - Early breast cancer

KW - Rapidly proliferating tumour

KW - Time to initiation of adjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84939565340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939565340&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.07.003

DO - 10.1016/j.ejca.2015.07.003

M3 - Article

C2 - 26206258

AN - SCOPUS:84939565340

VL - 51

SP - 1874

EP - 1881

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 14

M1 - 9535

ER -